nasdaq-mynz-mainzbiomed.png
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
December 19, 2024 08:01 ET | Mainz BioMed NV
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
nasdaq-mynz-mainzbiomed.png
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
December 16, 2024 17:00 ET | Mainz BioMed NV
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
nasdaq-mynz-mainzbiomed.png
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
December 12, 2024 20:00 ET | Mainz BioMed NV
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
nasdaq-mynz-mainzbiomed.png
Mainz Biomed Announces Stock Split
November 29, 2024 08:45 ET | Mainz BioMed NV
Mainz Biomed Announces Stock Split
nasdaq-mynz-mainzbiomed.png
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
October 21, 2024 08:01 ET | Mainz BioMed NV
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
nasdaq-mynz-mainzbiomed.png
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
October 08, 2024 08:01 ET | Mainz BioMed NV
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert
nasdaq-mynz-mainzbiomed.png
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
October 01, 2024 08:01 ET | Mainz BioMed NV
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
nasdaq-mynz-mainzbiomed.png
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
September 18, 2024 08:01 ET | Mainz BioMed NV
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
nasdaq-mynz-mainzbiomed.png
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
September 04, 2024 04:01 ET | Mainz BioMed NV
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of AI for the Expansion and Optimization of Biomarker Selection for PancAlert